GHRS vs. GSK

Last updated Jun 4, 2026

GHRS (GH Research PLC) and GSK (GlaxoSmithKline plc) are both stocks. Both are in the Healthcare sector — GHRS in Biotechnology, GSK in Drug Manufacturers - General. Over the past 3 years, GHRS returned 26.81%/yr vs 17.89%/yr for GSK. At a 0.04 correlation, their price movements are largely independent.

Performance

GHRS vs. GSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GH Research PLC (GHRS) and GlaxoSmithKline plc (GSK). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GHRS achieves a 92.36% return, which is significantly higher than GSK's 3.01% return.

GHRS

• 1D: -1.77%
• 1M: 12.63%
• YTD: 92.36%
• 6M: 69.89%
• 1Y: 102.24%
• 3Y*: 26.81%
• 5Y*: —
• 10Y*: —

GSK

• 1D: 1.47%
• 1M: -1.55%
• YTD: 3.01%
• 6M: 3.15%
• 1Y: 27.33%
• 3Y*: 17.89%
• 5Y*: 4.64%
• 10Y*: 3.96%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GHRS vs. GSK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GHRS GH Research PLC	92.36%	81.43%	20.69%	-40.33%	-58.34%	21.19%
GSK GlaxoSmithKline plc	3.01%	51.23%	-5.14%	9.71%	-33.41%	13.65%

Correlation

The correlation between GHRS and GSK is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.03
Correlation (3Y) Calculated over the trailing 3-year period	0.01
Correlation (All Time) Calculated using the full available price history since Jun 28, 2021	0.04

Fundamentals

Market Cap GHRS : $1.52B GSK : $101.28B
EPS GHRS : -$0.91 GSK : $2.85
PB Ratio GHRS : 5.75 GSK : 4.30
Total Revenue (TTM) GHRS : $0.00 GSK : $32.78B
Gross Profit (TTM) GHRS : -$268.00K GSK : $23.87B
EBITDA (TTM) GHRS : -$58.38M GSK : $11.30B

Return for Risk

GHRS vs. GSK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GHRS

GHRS Risk / Return Rank: 76
GHRS Sharpe Ratio Rank: 78
GHRS Sortino Ratio Rank: 77
GHRS Omega Ratio Rank: 75
GHRS Calmar Ratio Rank: 80
GHRS Martin Ratio Rank: 72

GSK

GSK Risk / Return Rank: 68
GSK Sharpe Ratio Rank: 72
GSK Sortino Ratio Rank: 66
GSK Omega Ratio Rank: 64
GSK Calmar Ratio Rank: 68
GSK Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GHRS vs. GSK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GH Research PLC (GHRS) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GHRS	GSK	Difference
Sharpe ratio: Return per unit of total volatility	1.31	1.03	+0.28
Sortino ratio: Return per unit of downside risk	2.10	1.57	+0.53
Omega ratio: Gain probability vs. loss probability	1.26	1.19	+0.07
Calmar ratio: Return relative to maximum drawdown	2.60	1.47	+1.13
Martin ratio: Return relative to average drawdown	4.28	3.45	+0.83
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GHRS vs. GSK - Sharpe Ratio Comparison

The current GHRS Sharpe Ratio is 1.31, which is comparable to the GSK Sharpe Ratio of 1.03. The chart below compares the historical Sharpe Ratios of GHRS and GSK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GHRS	GSK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.31	1.03	+0.28
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.19	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.17	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.06	0.32	-0.26

Drawdowns

GHRS vs. GSK - Drawdown Comparison

The maximum GHRS drawdown since its inception was -81.15%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for GHRS and GSK.

Drawdown Indicators

	GHRS	GSK	Difference
Max Drawdown Largest peak-to-trough decline	-81.15%	-55.70%	-25.45%
Max Drawdown (1Y) Largest decline over 1 year	-39.49%	-18.63%	-20.86%
Max Drawdown (3Y) Largest decline over 3 years	-62.83%	-28.46%	-34.37%
Max Drawdown (5Y) Largest decline over 5 years	—	-50.10%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-50.10%	—
Current Drawdown Current decline from peak	-12.44%	-17.43%	+4.99%
Average Drawdown Average peak-to-trough decline	-52.91%	-18.87%	-34.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.98%	7.94%	+16.04%

Volatility

GHRS vs. GSK - Volatility Comparison

GH Research PLC (GHRS) has a higher volatility of 15.01% compared to GlaxoSmithKline plc (GSK) at 5.40%. This indicates that GHRS's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GHRS	GSK	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.01%	5.40%	+9.61%
Volatility (6M) Calculated over the trailing 6-month period	55.30%	18.38%	+36.92%
Volatility (1Y) Calculated over the trailing 1-year period	78.50%	26.84%	+51.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	86.81%	25.01%	+61.80%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	86.81%	22.86%	+63.95%

Dividends

GHRS vs. GSK - Dividend Comparison

GHRS has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 3.48%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GHRS GH Research PLC	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GSK GlaxoSmithKline plc	3.48%	3.42%	4.60%	3.75%	5.47%	4.99%	5.59%	4.35%	5.65%	5.83%	6.86%	5.93%

Financials

Frequently Asked Questions

Can I hold both GHRS and GSK in my portfolio?

GHRS and GSK have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GHRS or GSK?

GHRS has higher volatility (15.01%) compared to GSK (5.40%). In terms of maximum drawdown, GHRS dropped -81.15% vs GSK's -55.70%.

Which has better risk-adjusted returns?

GHRS currently has the higher Sharpe Ratio (1.31 vs 1.03), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.